Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer.
Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nisticò C, Gasparro S, Barberi V, Ciolina M, Pescarmona E, Giannarelli D, Ciliberto G, Cognetti F, Giacomini P. Allegretti M, et al. Among authors: ciliberto g. Mol Cancer. 2021 Nov 29;20(1):151. doi: 10.1186/s12943-021-01438-z. Mol Cancer. 2021. PMID: 34839818 Free PMC article. No abstract available.
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA. Grimaldi AM, et al. Among authors: ciliberto g. Oncoimmunology. 2014 May 14;3:e28780. doi: 10.4161/onci.28780. eCollection 2014. Oncoimmunology. 2014. PMID: 25083318 Free PMC article.
Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.
Di Benedetto A, Ercolani C, Mottolese M, Sperati F, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Humphries MP, Di Lauro L, Barba M, Vitale I, Ciliberto G, Speirs V, De Maria R, Maugeri-Saccà M. Di Benedetto A, et al. Among authors: ciliberto g. Sci Rep. 2017 Aug 14;7(1):8078. doi: 10.1038/s41598-017-07366-7. Sci Rep. 2017. PMID: 28808232 Free PMC article.
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.
Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P. Pizzuti L, et al. Among authors: ciliberto g. Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16. Cancer Biol Ther. 2018. PMID: 29336662 Free PMC article.
Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
Melucci E, Casini B, Ronchetti L, Pizzuti L, Sperati F, Pallocca M, De Nicola F, Goeman F, Gallo E, Amoreo CA, Sergi D, Terrenato I, Vici P, Di Lauro L, Diodoro MG, Pescarmona E, Barba M, Mazzotta M, Mottolese M, Fanciulli M, Ciliberto G, De Maria R, Buglioni S, Maugeri-Saccà M. Melucci E, et al. Among authors: ciliberto g. J Transl Med. 2018 Feb 5;16(1):22. doi: 10.1186/s12967-018-1385-y. J Transl Med. 2018. PMID: 29402328 Free PMC article.
Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani C, Di Benedetto A, Blandino G, Ciliberto G, Mengarelli A, Rizzo MG. Marchesi F, et al. Among authors: ciliberto g. J Exp Clin Cancer Res. 2018 May 2;37(1):95. doi: 10.1186/s13046-018-0768-5. J Exp Clin Cancer Res. 2018. PMID: 29716630 Free PMC article.
Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer.
De Nicola F, Goeman F, Pallocca M, Sperati F, Pizzuti L, Melucci E, Casini B, Amoreo CA, Gallo E, Diodoro MG, Buglioni S, Mazzotta M, Vici P, Sergi D, Di Lauro L, Barba M, Pescarmona E, Ciliberto G, De Maria R, Fanciulli M, Maugeri-Saccà M. De Nicola F, et al. Among authors: ciliberto g. Oncogenesis. 2018 Jul 22;7(7):55. doi: 10.1038/s41389-018-0066-2. Oncogenesis. 2018. PMID: 30032163 Free PMC article.
Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
Pallocca M, Goeman F, De Nicola F, Melucci E, Sperati F, Terrenato I, Pizzuti L, Casini B, Gallo E, Amoreo CA, Vici P, Di Lauro L, Buglioni S, Diodoro MG, Pescarmona E, Mazzotta M, Barba M, Fanciulli M, De Maria R, Ciliberto G, Maugeri-Saccà M. Pallocca M, et al. Among authors: ciliberto g. J Transl Med. 2018 Sep 4;16(1):247. doi: 10.1186/s12967-018-1607-3. J Transl Med. 2018. PMID: 30180862 Free PMC article.
The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression.
Buglioni S, Melucci E, Sperati F, Pallocca M, Terrenato I, De Nicola F, Goeman F, Casini B, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vici P, Sergi D, Pizzuti L, Di Lauro L, Mazzotta M, Barba M, Fanciulli M, Vitale I, De Maria R, Ciliberto G, Maugeri-Saccà M. Buglioni S, et al. Among authors: ciliberto g. Oncoimmunology. 2018 Apr 24;7(8):e1457602. doi: 10.1080/2162402X.2018.1457602. eCollection 2018. Oncoimmunology. 2018. PMID: 30221053 Free PMC article.
524 results